secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jade Biosciences, Inc. (JBIO)
CIK:        0001798749
Form:       8-K
Filed at:   2026-06-04T21:09:05+00:00
Accession:  0001193125-26-257733
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jade Biosciences prices $150M public offering of 10M shares at $15/share
------------------------------------------------------------------------

- Priced public offering of 10,000,000 shares of common stock at $15.00 per share for gross proceeds of $150.0M.
- Net proceeds expected ~$140.3M (~$161.5M if underwriters’ 30-day option for 1.5M additional shares is exercised).
- Intends use net proceeds for clinical trials, preclinical studies, manufacturing, R&D, capex, working capital, and general corporate purposes.
- Jefferies, TD Cowen, UBS Investment Bank acting as joint book-running managers; offering expected to close June 5, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1798749/000119312526257733/0001193125-26-257733-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1798749/000119312526257733/d103726d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-257733

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer